KCT0012337进行中（未招募）2 期
Multi-center, Open-label, Single-arm Phase II Clinical trial of Sacituzumab-Govitecan plus Q901 in Advanced TNBC
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 19(Year) 至 No Limit（—）
- 性别
- All
入选标准
- •(1) Patients with histologically or cytologically confirmed triple-negative breast cancer (TNBC) who have received at least 2 prior lines of systemic anticancer therapy for recurrent, metastatic, or unresectable disease. TNBC is defined as estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative status.
- •ER-negative and PR-negative are defined as nuclear staining in <1% of cells by immunohistochemistry (IHC).
- •HER2-negative is defined by any of the following:
- •IHC 0 or 1+ without in-situ hybridization (ISH) results, or
- •IHC 2+ with negative ISH (single-probe ISH average HER2 gene copy number <4 signals/cell, or dual-probe ISH HER2/CEP17 ratio <2.0 with average HER2 gene copy number <4 signals/cell), or
- •Negative ISH without IHC results.
- •(2) Male or female patients aged =19 years.
- •(3) Patients who have received at least 2 prior lines of systemic anticancer therapy for recurrent, metastatic, or unresectable TNBC.
- •Prior therapy may include chemotherapy, immunotherapy, or targeted therapy.
- •There is no restriction on the type or sequence of prior therapies (however, prior treatment with a taxane-based regimen is required).
- •*Patients who received adjuvant/neoadjuvant therapy for surgically resectable breast cancer and relapsed within 12 months after completion of the last chemotherapy are considered to have received 1 line of chemotherapy.
- •(4) Patients who have provided written informed consent prior to any study-specific procedures.
- •(5) Patients with at least 1 measurable lesion per RECIST 1.1 on baseline CT.
- •(6) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •(7) Patients with adequate organ function as defined below. Transfusion or growth factor support is not permitted within 14 days prior to screening laboratory tests.
- •A. Absolute Neutrophil Count (ANC) = 1,500 cells/mm³
- •B. Platelets = 100,000/mm³
- •C. Hemoglobin = 9.0 g/dL
- •D. Total bilirubin = 1.5 × ULN
- •E. AST (SGOT) = 2.5 × ULN (= 5.0 × ULN if liver metastases are present)
- •F. ALT (SGPT) = 2.5 × ULN (= 5.0 × ULN if liver metastases are present)
- •G. Creatinine clearance = 60 mL/min calculated using the Cockcroft-Gault equation, or serum creatinine = 1.5 × ULN
- •(8) 12-lead ECG showing normal findings or non-clinically significant changes not requiring medical intervention.
- •(9) QTc interval = 470 msec and no history of Torsades de pointes.
- •(10) Women of childbearing potential who are not pregnant or breastfeeding must use an effective method of contraception from 2 weeks before the start of study treatment, during treatment, and until 7 months after completion of study treatment.
- •Women of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to the first dose of study drug. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test must be performed.
- •Women of childbearing potential must agree to use an adequate method of contraception (as described in Section 11.13), be surgically sterile, or abstain from heterosexual intercourse during the study and until 7 months after the last dose of study drug.
- •Women considered to be of non-childbearing potential are defined as follows; patients not meeting these criteria are considered to be of childbearing potential:
- •Women who have undergone surgical sterilization (bilateral salpingectomy, bilateral oophorectomy, or hysterectomy)
- •Women aged =55 years with no spontaneous menstruation for =12 months prior to rand
排除标准
- •(1) Prior treatment with a TROP2-targeted antibody-drug conjugate, or a history of receiving a selective CDK7 inhibitor including Q
- •(2) Severe cardiac disease (e.g., uncontrolled hypertension, congestive heart failure [NYHA class =2], ventricular arrhythmia, active ischemic heart disease, or history of myocardial infarction within the past 1 year).
- •(3) Current active hepatic or biliary disease (Gilbert's syndrome, asymptomatic gallstones, liver metastases, or stable chronic liver disease may be excluded from this criterion at the investigator's discretion).
- •(4) Patients with a clinically significant, uncontrolled medical condition that limits the ability to comply with study procedures, or other medical conditions that place the patient at an unacceptable risk of toxicity.
- •(5) Patients with symptomatic CNS metastases, or CNS metastases requiring local treatment (e.g., radiotherapy or surgery). Patients previously treated for brain metastases must be clinically and radiologically stable (no evidence of disease progression and all neurological symptoms returned to baseline from =4 weeks after treatment until study enrollment; no evidence of new or progressive brain metastases) and must not have received steroid therapy exceeding physiological doses (>10 mg prednisolone/day) for at least 2 weeks prior to administration of the study drug. Regardless of the above conditions, subjects with leptomeningeal carcinomatosis are not permitted.
- •(6) Concomitant use of known strong CYP3A4/5 inhibitors such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin, and nelfinavir.
- •(7) Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Patients who have completed curative therapy for HCV are eligible. For patients with evidence of chronic HBV infection, the HBV viral load must be undetectable at the time of enrollment.
- •(8) Patients with significantly impaired mental status, or psychological, familial, sociological, or geographical conditions that impede understanding of the study or potentially interfere with compliance with the study protocol and follow-up schedule.
- •(9) Patients diagnosed with another malignancy within 5 years. Exceptions are non-melanoma skin cancer treated with curative intent, in-situ disease treated with curative intent, thyroid cancer, or cervical intraepithelial carcinoma.
- •(10) Patients who are pregnant or breastfeeding, or who plan to conceive during the scheduled study period from the screening visit until 7 months after the last dose of study drug.
- •(11) Patients who received a live or live-attenuated vaccine within 30 days prior to the scheduled first dose of the study drug.
- •(12) Unresolved active systemic infection.
- •(13) In addition to the above criteria, the investigator may exclude a subject from the study if the subject is judged to have conditions that may compromise subject safety or the scientific validity of the study.
研究者
相似试验
尚未招募
不适用
BG-C137-101Advanced Solid TumorjRCT203125059119
撤回
1 期
Multicenter, open-label single arm phase I study evaluating the safety and efficacy of combined MB-CART19.1-IBK cells and the 2nd generation BTK-inhibitor Zanubrutinib in relapsed or refractory PCNSL
"Zanubrutinib and CAR T cells in R/R PCNSL: Z-CARP-Study"
A prospective non-randomized multicenter phase I studyrelapsed/ refractory Primary central nervous system lymphoma (r/r PCNSL)2024-520342-28-00Medizinische Universitaet Innsbruck5
尚未招募
2 期
Sacituzumab Govitecan and Q901 in Advanced TNBCTriple Negative Breast NeoplasmsNCT07788222Yonsei University48
尚未招募
2 期
A Study in Adults With Desmoid TumorsDesmoid TumorNCT07541430Elpiscience (Suzhou) Biopharma, Ltd.50
尚未招募
2 期
Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell LymphomaLarge B-Cell Lymphoma (LBCL)High-grade B-cell LymphomaNCT07774234The First Affiliated Hospital of Soochow University39